华润医药(03320.HK) 宣布，集团旗下“湘中制药”收到国家药品监督管理局颁发的左乙拉西坦口服溶液《药品注册证书》，并视同通过一致性评价。同时，集团旗下“天东制药”获得山东省药品监督管理局颁发的《药品GMP符合性检查告知书》，通过药品GMP符合性检查。
左乙拉西坦口服溶液是一种用于成人、儿童及一个月以上婴幼儿癫痫患者部分性发作的加用治疗药物。
天东制药的GMP检查范围包括以下生产线：肝素钠原料药生产线及那屈肝素钙原料药生产线。本次药品GMP符合性检查，是肝素钠原料药新工艺、那屈肝素钙原料药上市前的首次药品GMP符合性检查。(su/a)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-03 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.